Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
SelectImmune Pharma AB and Swedish Orphan Biovitrum AB (SOBI) have signed an agreement to collaborate on the use of the existing SOBI drug Kineret[®] (anakinra) for the indications of cystitis and bladder pain syndrome.
As of March 29[th], SelectImmune Pharma AB has entered into a collaboration agreement with SOBI to develop anakinra for the treatment of patients with cystitis or bladder pain syndrome. Extensive research into the molecular mechanism of cystitis at Lund University has identified interleukin-1 as a major regulator of inflammation and disease in acute cystitis. The interleukin-1 receptor antagonist (IL1-RA) anakinra[ ]inhibits inflammation and infection in animal models of cystitis. SelectImmune Pharma's patents cover the use of anakinra for the treatment of cystitis and chronic bladder pain syndrome.
SelectImmune Pharma is pursuing clinical trials to address the therapeutic efficacy here.[.] A collaboration with SOBI will significantly contribute to this process. SOBI will supply active ingredient and placebo for future studies of their existing drug Kineret[®] as a treatment for cystitis and bladder pain syndrome.
The agreement defines how SelectImmune Pharma remains in control of upcoming clinical trials and SOBI the provider of drug and placebo. The agreement further emphasizes the scientific potential of this collaboration. The parties further intend to negotiate a commercialization agreement for the indications protected by SelectImmune Pharma's patent rights.
"We are delighted to have access to the vast experience of SOBI and their knowledge of the different clinical indications where Kineret[®] has been used so successfully," says Catharina Svanborg, Chairman, SelectImmune Pharma.
"This agreement is of great value to SelectImmune Pharma and we very much look forward to the collaboration" says Ann Gidner, CEO, SelectImmune Pharma.
For more information, please contact
Catharina Svanborg
Chairman
SelectImmune Pharma AB
Phone +46 709 42 65 49
catharina.svanborg@med.lu.se
Ann Gidner
CEO
SelectImmune Pharma AB
Phone +46 768 17 14 14
ann.gidner@selectImmune.com
This disclosure contains information that SelectImmune is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 29-03-2022 16:23 CET.